-
公开(公告)号：US5643731A
公开(公告)日：1997-07-01
申请号：US467943
申请日：1995-06-06
申请人： Klaus Bosslet , Peter Hermentin , Hans Harald Sedlacek , Bernhard Auerbach , Peter Pfleiderer , Rolf Muller
发明人： Klaus Bosslet , Peter Hermentin , Hans Harald Sedlacek , Bernhard Auerbach , Peter Pfleiderer , Rolf Muller
IPC分类号： G01N33/53 , G01N33/532 , G01N33/543 , G01N33/574 , G01N33/68
CPC分类号： G01N33/54306 , G01N33/532 , G01N33/57473 , G01N2333/82 , Y10S435/969 , Y10S435/971 , Y10S435/975 , Y10S436/824
摘要： The invention relates to a method of using a pair of leucine zipper peptides for in vitro diagnosis, in particular, for the immunochemical detection and determination of an analyte in a biological liquid. In one method, the first leucine zipper peptide is immobilized by attaching it to a solid support, the second leucine zipper peptide is coupled to a specific binding partner for the analyte, the two peptides are brought into contact, the sample of the biological liquid is brought into contact with the immobilized first peptide and the specific binding partner for the analyte, and the amount of analyte bound to the binding partner is determined. The leucine zipper peptides are preferably v-fos and c-jun.
摘要翻译： 本发明涉及一种使用一对亮氨酸拉链肽进行体外诊断的方法，特别是用于生物液体中分析物的免疫化学检测和测定。 在一种方法中，通过将第一亮氨酸拉链肽连接到固体支持物上来固定第一亮氨酸拉链肽，将第二亮氨酸拉链肽与分析物的特异性结合配偶体偶联，使两个肽接触，生物液体的样品为 与固定化的第一肽和分析物的特异性结合配偶体接触，并测定与结合配偶体结合的分析物的量。 亮氨酸拉链肽优选为v-fos和c-jun。
-
2.发明授权Monoclonal antibodies (MAbs) against tumor-associated antigens, the preparation and use thereof 失效针对肿瘤相关抗原的单克隆抗体（MAb），其制备和应用公开(公告)号：US06926896B2
公开(公告)日：2005-08-09
申请号：US08356791
申请日：1994-12-13
IPC分类号： A61K38/00 , A61K39/395 , A61K47/00 , A61K47/48 , A61K49/00 , A61K51/00 , A61K51/10 , C07K16/00 , C07K16/30 , C07K19/00 , C12P21/08 , G01N33/577
CPC分类号： C07K16/3084 , A61K38/00 , A61K47/68 , A61K47/6815 , A61K47/6817 , A61K47/6851 , A61K51/1045 , C07K16/30 , C07K2317/24 , C07K2317/56 , C07K2317/76 , C07K2319/00 , C07K2319/30
摘要： The invention relates to murine monoclonal antibodies (MAbs), A, B, C and D, which are directed against tumor-associated antigens. The nearly complete nucleotide sequences of the V genes of these MAbs are described, so that the relevant variable domains can be put together to give chimeric MAbs, or “humanized” MAbs are obtained by inserting the hypervariable regions (complementarity determining regions=CDR) into a human MAb framework. Antibody constructs of this type can be employed in human therapy and in vivo diagnosis without the disadvantages observed with murine MAbs.
摘要翻译： 本发明涉及针对肿瘤相关抗原的鼠单克隆抗体（MAb），A，B，C和D。 描述了这些MAb的V基因的几乎完整的核苷酸序列，使得相关的可变结构域可以放在一起以产生嵌合的MAb，或者通过将高变区（互补决定区= CDR）插入到 人类的MAb框架。 这种类型的抗体构建体可以用于人类治疗和体内诊断，而不存在用鼠MAb观察到的缺点。
-
3.发明授权Chimeric antibody against tumor associated antigens and its use in diagnosing tumors 失效针对肿瘤相关抗原的嵌合抗体及其在诊断肿瘤中的应用公开(公告)号：US07662383B2
公开(公告)日：2010-02-16
申请号：US12068545
申请日：2008-02-07
IPC分类号： A61K39/395 , C07K16/30 , C12P21/08
CPC分类号： C07K16/3084 , A61K38/00 , A61K47/68 , A61K47/6815 , A61K47/6817 , A61K47/6851 , A61K51/1045 , C07K16/30 , C07K2317/24 , C07K2317/56 , C07K2317/76 , C07K2319/00 , C07K2319/30
摘要： The invention relates to murine monoclonal antibodies (MAbs), A, B, C and D, which are directed against tumor-associated antigens. The nearly complete nucleotide sequences of the V genes of these MAbs are described, so that the relevant variable domains can be put together to give chimeric MAbs, or “humanized” MAbs are obtained by inserting the hypervariable regions (complementarity determining regions=CDR) into a human MAb framework. Antibody constructs of this type can be employed in human therapy and in vivo diagnosis without the disadvantages observed with murine MAbs.
摘要翻译： 本发明涉及针对肿瘤相关抗原的鼠单克隆抗体（MAb），A，B，C和D。 描述了这些MAb的V基因的几乎完整的核苷酸序列，使得相关的可变结构域可以放在一起以产生嵌合的MAb，或者通过将高变区（互补决定区= CDR）插入到 人类的MAb框架。 这种类型的抗体构建体可以用于人类治疗和体内诊断，而不存在用鼠MAb观察到的缺点。
-
4.发明申请Monoclonal antibodies (MAbs) against tumor-associated antigens, the preparation and use thereof 失效针对肿瘤相关抗原的单克隆抗体（MAb），其制备和应用公开(公告)号：US20090246132A1
公开(公告)日：2009-10-01
申请号：US12068545
申请日：2008-02-07
IPC分类号： A61K51/10 , C07K16/18 , C12N9/00 , A61K39/395 , C07K19/00 , C07K16/46 , C12P21/02 , A61P35/00 , G01N33/53
CPC分类号： C07K16/3084 , A61K38/00 , A61K47/68 , A61K47/6815 , A61K47/6817 , A61K47/6851 , A61K51/1045 , C07K16/30 , C07K2317/24 , C07K2317/56 , C07K2317/76 , C07K2319/00 , C07K2319/30
摘要： The invention relates to murine monoclonal antibodies (MAbs), A, B, C and D, which are directed against tumor-associated antigens. The nearly complete nucleotide sequences of the V genes of these MAbs are described, so that the relevant variable domains can be put together to give chimeric MAbs, or “humanized” MAbs are obtained by inserting the hypervariable regions (complementarity determining regions=CDR) into a human MAb framework. Antibody constructs of this type can be employed in human therapy and in vivo diagnosis without the disadvantages observed with murine MAbs.
摘要翻译： 本发明涉及针对肿瘤相关抗原的鼠单克隆抗体（MAb），A，B，C和D。 描述了这些MAb的V基因的几乎完整的核苷酸序列，使得相关的可变结构域可以放在一起以产生嵌合的MAb，或者通过将高变区（互补决定区= CDR）插入到 人类的MAb框架。 这种类型的抗体构建体可以用于人类治疗和体内诊断，而不存在用鼠MAb观察到的缺点。
-
5.发明授权Gene therapy of tumors with an endothelial cell-specific, cell cycle-dependent active compound 失效具有内皮细胞特异性，细胞周期依赖性活性化合物的肿瘤的基因治疗
公开(公告)号：US5830880A
公开(公告)日：1998-11-03
申请号：US793107
申请日：1997-04-18
申请人： Hans-Harald Sedlacek , Klaus Bosslet , Rolf Muller
发明人： Hans-Harald Sedlacek , Klaus Bosslet , Rolf Muller
IPC分类号： C12N15/09 , A61K9/127 , A61K35/76 , A61K38/00 , A61K38/21 , A61K38/22 , A61K38/44 , A61K38/46 , A61K38/55 , A61K39/395 , A61K47/48 , A61K48/00 , A61P7/02 , A61P9/08 , A61P25/00 , A61P35/00 , A61P43/00 , C07K14/47 , C07K14/475 , C12N15/00 , C12N15/85 , C12P21/02 , C12R1/91 , C12R1/92 , C07H21/04
CPC分类号： A61K48/00 , C12N15/85 , A61K38/00 , C12N2830/15 , C12N2830/30 , C12N2830/85
摘要： A DNA sequence for the gene therapy of tumors is described. In its essential elements, the DNA sequence is composed of an activator sequence, a promoter module and a gene for the active substance. The activator sequence is activated, in a cell-specific manner, in proliferating endothelial cells or in cells which are adjacent to these endothelial cells. This activation is regulated by the promoter module in a cell cycle-specific manner. The active substance is an inhibitor of angiogenesis or a cytostatic or cytotoxic molecule. The DNA sequence is inserted into a viral or non-viral vector which is supplemented with a ligand which possesses affinity for the activated endothelial cell.
摘要翻译： PCT No.PCT / EP95 / 03370 Sec。 371日期1997年4月18日 102（e）1997年4月18日PCT PCT 1995年8月25日PCT公布。 出版物WO96 / 06940 日期1996年3月7日描述了肿瘤基因治疗的DNA序列。 在其基本元素中，DNA序列由活化物序列，启动子模块和活性物质的基因组成。 活化剂序列以细胞特异性方式在增殖的内皮细胞或与这些内皮细胞相邻的细胞中活化。 该激活由细胞周期特异性方式由启动子模块调节。 活性物质是血管发生抑制剂或细胞抑制或细胞毒性分子。 将DNA序列插入病毒或非病毒载体中，其补充有对活化的内皮细胞具有亲和力的配体。
-
6.发明授权Antigenic constructs of major histocompatibility complex class I antigens with specific carrier molecules, the preparation and use thereof 失效具有特异性载体分子的主要组织相容性复合物I类抗原的抗原构建体，其制备和应用公开(公告)号：US06548067B1
公开(公告)日：2003-04-15
申请号：US08460569
申请日：1995-06-02
IPC分类号： A61K3900
CPC分类号： B82Y5/00 , A61K38/00 , A61K47/6898 , C07K14/70539 , C07K16/00 , C07K17/02 , C07K2319/00 , C07K2319/02
摘要： Antigenic constructs which result from linkage of major histocompatibility complex (MHC) class I antigens with specific carrier molecules are described. The linkage is effected N- or C-terminally by covalent bonding or, for example, in the case of non-covalent bonding by an avidin/biotin bridge. The specific carrier molecules bind selectively to target cells and are preferably monoclonal antibodies. Processes of genetic manipulation for the preparation of such constructs are indicated. Antigenic constructs according to the invention are used to damage or eliminate target cells.
摘要翻译： 描述了由主要组织相容性复合体（MHC）I类抗原与特异性载体分子的连接产生的抗原构建体。 通过共价键进行N-或C-末端的连接，或者例如在通过抗生物素蛋白/生物素桥的非共价结合的情况下。 特异性载体分子选择性地结合靶细胞，优选单克隆抗体。 指出用于制备这种构建体的遗传操作过程。 根据本发明的抗原构建体用于损伤或消除靶细胞。
-
7.发明授权Glycosyl-etoposide prodrugs, a process for preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates 失效糖基 - 依托泊苷前药，其制备方法及其与功能化肿瘤特异性酶缀合物的组合公开(公告)号：US06475486B1
公开(公告)日：2002-11-05
申请号：US09343698
申请日：1999-06-30
申请人： Cenek Kolar , Jörg Czech , Klaus Bosslet , Gerhard Seemann , Hans-Harald Sedlacek , Dieter Hoffman
发明人： Cenek Kolar , Jörg Czech , Klaus Bosslet , Gerhard Seemann , Hans-Harald Sedlacek , Dieter Hoffman
IPC分类号： A61K39395
CPC分类号： B82Y5/00 , A61K47/6815 , A61K2039/505 , C07K16/3007 , C07K2317/24 , C07K2319/00
摘要： The present invention relates to glycosyl-etoposide prodrugs, a process for the preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates for treating cancers.
摘要翻译： 本发明涉及糖基 - 依托泊苷前药，其制备方法及其与用于治疗癌症的官能化肿瘤特异性酶缀合物的组合的用途。
-
公开(公告)号：US06294172B1
公开(公告)日：2001-09-25
申请号：US08383678
申请日：1995-02-01
申请人： Klaus Bosslet , Roland Kurrle , Hans Harald Sedlacek , Ernst-Jurgen Kanzy , Takako Katoh , Hans Ulrich Schorlemmer , Gerhard Luben
发明人： Klaus Bosslet , Roland Kurrle , Hans Harald Sedlacek , Ernst-Jurgen Kanzy , Takako Katoh , Hans Ulrich Schorlemmer , Gerhard Luben
IPC分类号： A61K39395
CPC分类号： C07K16/3007 , A61K39/0011 , A61K47/6851 , A61K51/1045 , A61K2123/00 , C07K16/30 , C07K16/303 , G01N33/57415 , G01N33/57423 , G01N33/57438 , G01N33/57449 , G01N33/57492
摘要： Monoclonal antibodies with specificity for membrane-associated antigens and methods of using them in detection of tumor-associated antigens arc described.
摘要翻译： 描述了具有膜相关抗原特异性的单克隆抗体及其在肿瘤相关抗原检测中的应用。
-
9.发明授权Glycosyl-etoposide prodrugs, a process for preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates 失效糖基 - 依托泊苷前药，其制备方法及其与功能化肿瘤特异性酶缀合物的组合公开(公告)号：US07241595B2
公开(公告)日：2007-07-10
申请号：US10128493
申请日：2002-04-24
IPC分类号： C12P19/60
CPC分类号： B82Y5/00 , A61K38/00 , A61K47/6815 , A61K47/6851 , A61K47/6899 , A61K2039/505 , C07H17/04 , C07K16/30 , C07K16/3007 , C07K2317/24 , C07K2319/00 , C12N9/16 , C12N9/2434 , C12Y301/03001 , C12Y302/01031
摘要： The present invention relates to glycosyl-etoposide prodrugs, a process for the preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates for treating cancers.
摘要翻译： 本发明涉及糖基 - 依托泊苷前药，其制备方法及其与用于治疗癌症的官能化肿瘤特异性酶缀合物的组合的用途。
-
公开(公告)号：US06610299B1
公开(公告)日：2003-08-26
申请号：US08325955
申请日：1994-10-19
申请人： Cenek Kolar , Jörg Czech , Klaus Bosslet , Gerhard Seemann , Hans-Harald Sedlacek , Dieter Hoffmann
发明人： Cenek Kolar , Jörg Czech , Klaus Bosslet , Gerhard Seemann , Hans-Harald Sedlacek , Dieter Hoffmann
IPC分类号： A61K3944
CPC分类号： B82Y5/00 , A61K38/00 , A61K47/549 , A61K47/6815 , A61K47/6851 , A61K47/6899 , A61K2039/505 , C07H17/04 , C07K16/30 , C07K16/3007 , C07K2317/24 , C07K2319/00 , C12N9/2434 , C12Y302/01031
摘要： The present invention relates to glycosyl-etoposide prodrugs, a process for the preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates for treating cancers.
-
-
-
-
-
-
-
-
-
搜索结果
56 条记录 (耗时 0.028 秒)
